Aim Immunotech【0A4Y】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

買値

売値

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

発行済株式数

48,842,000

配当利回り

PER

-3.04

1 株当たり利益 (EPS)

-0.59

歳入

202k

純利益

-28.96M

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.aimimmuno.com

本社

Wilmington, Delaware, USA

設立

Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the ロンドン証券取引所 with ticker 0A4Y. The last closing price for Aim Immunotech was -. Over the last year, Aim Immunotech shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Aim Immunotech currently has 48,842,000 shares in issue. Aim Immunotech has a price to earnings ratio (PE ratio) of -3.04.

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue OCALA, Fla., Dec. 12, 2024 (GLOBE...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort to...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA, Fla...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to address...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0A4Y - Frequently Asked Questions (FAQ)

What is the current Aim Immunotech share price?

The current share price of Aim Immunotech is US$ 0.00

How many Aim Immunotech shares are in issue?

Aim Immunotech has 48,842,000 shares in issue

What is the 1 year trading range for Aim Immunotech share price?

Aim Immunotech has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Aim Immunotech?

The price to earnings ratio of Aim Immunotech is -3.04

What is the cash to sales ratio of Aim Immunotech?

The cash to sales ratio of Aim Immunotech is 439.02

What is the reporting currency for Aim Immunotech?

Aim Immunotech reports financial results in USD

What is the latest annual turnover for Aim Immunotech?

The latest annual turnover of Aim Immunotech is USD 202k

What is the latest annual profit for Aim Immunotech?

The latest annual profit of Aim Immunotech is USD -28.96M

What is the registered address of Aim Immunotech?

The registered address for Aim Immunotech is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Aim Immunotech website address?

The website address for Aim Immunotech is www.aimimmuno.com

Which industry sector does Aim Immunotech operate in?

Aim Immunotech operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
TIRTiger Royalties And Investments Plc	0.15p (50.00%)	3.41M
BAYBay Capital Plc	5.50p (19.57%)	209.68k
MASTMast Energy Developments Plc	0.19p (18.75%)	20.09M
MHNMenhaden Resource Efficiency Plc	148.50p (18.33%)	1M
ZENZenith Energy Ltd.	2.50p (16.28%)	3.93M
TRYBTribe Technology Plc	0.115p (-79.09%)	24.27M
NMTNeometals Ltd	2.75p (-35.29%)	49.4k
SNGSynairgen Plc	2.46p (-34.31%)	4.31M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M
AYMAnglesey Mining Plc	0.70p (-17.65%)	2.99M
NTVONativo Resources Plc	0.002p (5.26%)	971.94M
TRPTower Resources Plc	0.035p (9.38%)	620.03M
LLOYLloyds Banking Group Plc	54.16p (-0.26%)	341.48M
ORCPOracle Power Plc	0.0255p (-1.92%)	192.93M
TM1Technology Minerals Plc	0.185p (-26.00%)	174.03M